Peripheral arterial disease (PAD) is a major health care problem. There have been limited advances in medical therapies, and a huge burden of symptomatic patients with intermittent claudication and critical limb ischemia who have limited treatment options. Angiogenesis is the growth and proliferation of blood vessels from existing vasculature. For approximately 2 decades, "therapeutic angiogenesis" has been studied as an investigational approach to treat patients with symptomatic PAD. Despite literally hundreds of positive preclinical studies, results from human clinical studies thus far have been disappointing. Here we present an overview of where the field of therapeutic angiogenesis stands today and examine lessons learned from previously conducted clinical trials. The objective is not to second-guess past efforts but to place the lessons in perspective to allow for trial success in the future to improve agent development, trial design, and ultimately, clinical outcomes for new therapeutics for PAD. (J Am Coll Cardiol Basic Trans Science 2017;2:503-12)
I n the spring of 2016, AnGes (a biotechnology company based in Japan) announced the termination of the multinational phase III AGILITY (Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia) trial (NCT02144610) of the hepatocyte growth factor (HGF) plasmid for critical limb ischemia (CLI) (1) . This announcement may well end gene therapy trials for therapeutic angiogenesis for peripheral arterial disease (PAD). In <20 years, this field of investigation moved from being one of the most promising, with more than a dozen different agents having been developed and Table 1 contains a partial list of the studies). Overall, the results of these studies are disappointing, and they did not lead to advances in patientdirected therapies.
The first question that could be asked, "Was PAD the right area to pursue for thera- (3, 4) . In patients over 50 years of age, 40% to 50% will present with atypical leg symptoms, 10% to 35% with classic intermittent claudication, and 1% to 2% with threatened limb (5, 6) . Medical therapy with statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and antiplatelet agents have been shown to reduce morbidity and mortality related to cardiovascular events, but the effects of these agents on leg symptoms or disease progression are largely absent, with only rare positive reports (7) . Today, only supervised walking programs (with limited availability) and cilostazol (approved in 1999) have shown symptomatic benefit with improved peak walking time (PWT). The main treatment for lifestyle-limiting claudication and CLI has been revascularization, either surgical or endovascular. However, even with advances in surgical and endovascular technology, 20% to 40% of patients with CLI are not anatomically amenable to revascularization or have failed revascularization (8) (9) (10) . The growing clinical burden coupled with the unmet clinical need supported investigation into this area. Tables 2 and 3 provide the overview for designing early-and late-stage clinical trials, respectively.
Beyond representing an unmet clinical need in PAD, the leg was easily assessable for "agent" administration (either by an intravascular or a percutaneous approach), and this is certainly true in contrast to the heart. Easy access allowed for the exploration of different routes of delivery, multiple courses of treatment, and most importantly, allowed for randomized controlled trials. Despite these advantages, in reality, different delivery strategies were not well explored in early clinical trials. This approach may also have led to a false sense of security, because although delivery to the human leg is far easier than the heart, the human leg is vastly different in scale from the mouse leg, which was the site of early agent development. Also, although accessibility allowed easy imaging of the leg, imaging methods, such as perfusion imaging of the leg lag behind the heart. Because the goal of therapeutic angiogenesis was to improve blood flow to the ischemic muscles and soft tissue of the distal leg, the lack of direct imaging tools, in retrospect, was a major limitation in early agent development.
Human studies of therapeutic angiogenesis agents in PAD were conducted with protein, modified and unmodified plasmid deoxyribonucleic acid (DNA), and replication-deficient adenoviral vectors, and for some factors, the same agent was delivered in multiple ways. Protein therapy, which involves introduction of recombinant protein to the target site to promote angiogenesis, fell out of favor quite early at least in part due to the disappointing results in trials in coronary artery disease, and the short protein halflife was thought to limit target exposure to angiogenic stimulus (11) . The disadvantages were obvious, but the advantages of knowing pharmacokinetics and pharmacodynamics of recombinant proteins were clearly overlooked. Gene therapy sought to deliver an agent by plasmid nucleic acid or a virus vector/ plasmid, and had the potential advantage of sustaining production of the angiogenic agent compared with protein therapy. Was this "potential benefit" really explored in detail, or were many of the limitations of gene therapy superficially addressed or even ignored? First, for many of the angiogenic agents it was difficult, or even not possible, to measure gene expression in the target tissue. In a trial that used a replication-deficient adenovirus expressing hypoxiainducible factor 1-a, there was no evidence for enhanced gene expression of targets downstream of the transcription factor. The most studied vectors for gene delivery have been adenovirus gene delivery and plasmid gene delivery systems, both of which had the potential for vector-limiting toxicity (12) .
Significant concerns about the safety of adenovirus gene delivery were raised after the death of a patient with ornithine transcarbamylase deficiency who received 4 Â 10 13 particles of the virus intravascularly, which triggered significant immune response, systemic inflammatory response syndrome, disseminated intravascular coagulation, and eventual death (13, 14) . Additionally, in phase I and II cancer trials, the maximal tolerated dose was 2.5 Â 10 13 particles secondary to hypotension and cardiac output suppression (13) . Evidence supports the theory of immune response activation by plasmid DNA. It has been noted that there are greater amounts of unmethylated CpG motifs in plasmids than in eukaryotic cell DNA, which is thought to interact with Toll-like receptors and activate an immune response (15) .
Also, although a comprehensive review of preclinical studies is beyond the scope of this review, it is interesting to note this example: preclinical PAD studies used doses of 2 to 4 mg, and in the corresponding human studies, 0.4 mg naked plasmid HGF was delivered to assess for allergic reaction followed by 4 injections of 0.5 mg at 2 weeks and 4 injections of 0.5 mg at 4 weeks, for a total of 4 mg (16) . Should one really have expected 1:1 dosing moving from the small mouse to human? This is just one of several questions outlined in Table 4 that deserve consideration in gene therapy trials.
For the purposes of this review, clinical trial results will be organized around the growth factor products that have bene studied most extensively, which include VEGF, fibroblast growth factor (FGF), and HGF. Table 2 . Iyer and Annex , and yet differences between these isoforms were never systematically explored. Also, it is generally assumed that the lack of VEGF in the muscle of patients in PAD is not the limiting problem, and therefore, the problem in the lack of VEGF activation is likely downstream of the VEGF receptor (21) . Given that the change in VEGF following intramuscular gene transfer in humans was likely small, it would have been ideal to quantify the change in VEGF protein in the muscle after IM injections and compare it with what was found in preclinical models. Also, our understanding of the complexity of the biology of the VEGF receptor-ligand system is continuing to evolve.
VEGF CLINICAL TRIALS
Human studies drove some of the preclinical studies in VEGF, but it is yet to be determined whether these will translate into clinical reality (22) .
FGF CLINICAL TRIALS
FGF is a family of heparin-binding angiogenic growth factors that have been shown to regulate vascular development and various cellular pathways, as well as play a significant role in angiogenesis (23) . In particular, FGF1 (aka acidic-FGF) and FGF2 (basic FGF) have been studied in promoting angiogenesis in PAD (24, 25 (27) . Although the regimen was not likely to be clinically practical, this study provided the most convincing evidence that therapeutic angiogenesis could be achieved in humans (28) . There was a significant increase in toe-brachial index and in pain assessment as per visual analogue score.
HGF CLINICAL TRIALS
There was no significant in amputation-free survival or mortality (33) . These results have sparked interest for a larger phase III trial that has been terminated. In 
BARRIERS TO SUCCESS OF CLINICAL TRIALS
The results in late-stage clinical trials, especially when looking at clinical outcomes such as limb salvage and amputation, have been underwhelming.
There are several factors that are likely responsible for these disappointing results.
PRECLINICAL MODELS. There are a number of differences between preclinical animal models and patients with PAD and particularly CLI. The endogenous response to hind limb ischemia in wild-type mouse models, even with complete inflow occlusion, is robust: often normal or near-normal perfusion is present by 2 to 3 weeks in many but not all inbred mouse strains (38) . The endothelium and endothelial function is normal in wild-type mice and is known to be abnormal in patients with PAD (39, 40) . In addition to this, preclinical animal models tend to be younger, healthier, and with less comorbidities, all of which likely contribute to the less robust angiogenic response in patients with PAD (34, 41, 42) . Despite these limitations, in general, what is bad for humans with PAD (i.e., diabetes) is also bad for mice with experimental PAD (43) . What is clear is that preclinical studies should be conducted in a background where efficacy is difficult, not easy, to achieve.
PATIENT SELECTION. Therapeutic angiogenesis has been studied in patients with intermittent claudication and CLI. The trials that included patients with intermittent claudication have particularly disappointing results (12, 19, 44, 45) . CLI trials mainly have been restricted to patients who cannot be revascularized, otherwise known as no-option CLI, and a significant amount of neovascularization and increased collateral blood flow is expected to be required to see clinical improvement in these patients (46 Therapeutic Angiogenesis for PAD
